258 related articles for article (PubMed ID: 32575752)
1. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.
Fleming BD; Ho M
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32575752
[TBL] [Abstract][Full Text] [Related]
2. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Fleming BD; Ho M
Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
[TBL] [Abstract][Full Text] [Related]
4. DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study.
Hashemi Yeganeh H; Heiat M; Kieliszek M; Alavian SM; Rezaie E
Toxins (Basel); 2021 Oct; 13(11):. PubMed ID: 34822533
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
[TBL] [Abstract][Full Text] [Related]
6. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.
Wang C; Gao W; Feng M; Pastan I; Ho M
Oncotarget; 2017 May; 8(20):32450-32460. PubMed ID: 27419635
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
[TBL] [Abstract][Full Text] [Related]
8. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
9. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma.
Wu T; Song Z; Huang H; Jakos T; Jiang H; Xie Y; Zhu J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109393. PubMed ID: 36375323
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect.
Heiat M; Hashemi Yeganeh H; Alavian SM; Rezaie E
Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34679012
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
12. GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling.
Pan J; Li N; Renn A; Zhu H; Chen L; Shen M; Hall MD; Qian M; Pastan I; Ho M
Mol Cancer Ther; 2022 Jun; 21(6):960-973. PubMed ID: 35312769
[TBL] [Abstract][Full Text] [Related]
13. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
14. A New Combination: Anti Glypican-3 scFv and Diphtheria Toxin with the Best Flexible Linker.
Hashemi Yeganeh H; Heiat M; Alavian SM; Rezaei E
Protein J; 2022 Oct; 41(4-5):527-542. PubMed ID: 36001255
[TBL] [Abstract][Full Text] [Related]
15. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
17. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
[TBL] [Abstract][Full Text] [Related]
18. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
19. Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.
Liu X; Tan Q; Wen J; Wang X; Yang G; Li Y; Lu M; Ye W; Si A; Ma S; Ding T; Sun L; Liu F; Zhang M; Jiang T; Gao W
J Transl Med; 2023 Aug; 21(1):572. PubMed ID: 37626430
[TBL] [Abstract][Full Text] [Related]
20. Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.
Müller F; Cunningham T; Liu XF; Wayne AS; Pastan I
Clin Cancer Res; 2016 Oct; 22(19):4913-4922. PubMed ID: 27114443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]